App-Quantinova.ai

Increasing Primary Incidence of Hepatitis C Among HIV‐Infected Men Who Have Sex with Men in San Diego; a Pooled Analysis of Two Large Clinics from 2000‐2015

Antoine Chaillon - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

Methamphetamine

Biliary reconstruction following transplantation of a bio‐engineered bile duct incorporating primary human cholangiocyte organoids

Fotios Sampaziotis - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

A risk prediction score based on magnetic resonance cholangiopancreatography (MRCP) accurately predicts disease progression in patients with primary sclerosing cholangitis (PSC)

Andrew J. Muir - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Primary sclerosing cholangitis

Simtuzumab

Nivolumab in Sorafenib‐Naive and ‐Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040

Bruno Sanaro - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Liver cancer

Nivolumab

Identification Of Novel Viral Single Nucleotide Variants Associated With Baseline HBV DNA Levels And HBeAg Status In Chronic Hepatitis B Patients.

Kosh Agarwal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

Tenofovir disoproxil fumarate

Trends in pregnancy in women with liver disease: 1983 ‐ 2017

Tiong Yeng Lim - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

ZFP36L1 controls adiposity and steatosis via post‐transcriptional regulation of bile acid metabolism

Elizabeth Tarling - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Fatty Liver Disease

N/A

Performance of liver stiffness by FibroScan in a Large Prospective Multicenter UK Study: Applicability, Reliability, Diagnostic Performance and Influence of The Probe Type And Of Steatosis on the Liver Stiffness Measurement

Peter J. Eddowes - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Nonalcoholic fatty liver disease

M-118

Adherence to Pangenotypic Glecaprevir/ Pibrentasvir Treatment and SVR12 in HCV‐ infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program

Ashley S. Brown - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

Pibrentasvir

The road to elimination of Hepatitis C: Analysis of SVR versus new HCV infections in 91 countries

Andrew M. Hill - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis C

N/A

Increased myocardial extracellular volume define patients with more advanced cirrhosis and at higher risk of mortality: Results from a cardiac MRI and Echo study

Signe Wiese - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Cirrhosis

N/A

Ursodeoxycholic Acid is Associated with a Prolonged Transplant‐free Survival in All Patients with Primary Biliary Cholangitis ‐ there is no such thing as non‐response.

Adriaan J. van der Meer - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary biliary cirrhosis

Ursodeoxycholic acid

Radiologic progression in primary sclerosing cholangitis (PSC) by two‐dimensional magnetic resonance cholangiopancreatography (MRCP): Prospective data from a randomized controlled trial

Andrew J. Muir - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Primary sclerosing cholangitis

Alkaline phosphatase

Time‐dependent factors associated with diminished transplant‐free survival in patients with primary biliary cholangitis and an optimal response to ursodeoxycholic acid after one year of treatment

Willem J. Lammers - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary biliary cirrhosis

Alkaline phosphatase

Elevated Hepatic Biochemistry Predicts Recurrent Primary Sclerosing Cholangitis in the First 12 Months Following Liver Transplantation

Wasilenko T. Shawn - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary sclerosing cholangitis

N/A

Recurrence of Primary Biliary Cholangitis after Liver Transplantation Affects Graft Survival: A Multi‐Center Study from the Global PBC Study Group

Aldo J. Monta no-Loza - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary biliary cirrhosis

N/A

Quantification of biliary tree volume in patients with PSC using three dimensional (3D) reconstruction of magnetic resonance cholangiopancreatography (MRCP): Clinical associations and prognostic significance

Clare Tempanv-Afdhal - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Ascending cholangitis

Simtuzumab

Moving from early to moderate or advanced biochemical disease stage during follow‐up is associated with an increasing risk of clinical events in primary biliary cholangitis patients.

Nikolaos K. Gatselis - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Primary biliary cirrhosis

N/A

Serum Metabonomic and Gut Microbial Profile in Patients with Primary Biliary Cholangitis with Pruritus and the Effect of Ileal Bile Acid Transporter Inhibition

Vinod S. Hegade - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Primary biliary cirrhosis

N/A

Gut derived p7+CD8+ T cells are enriched in the hepatic tissue of PSC‐IBD patients implicating a role for extra intestinal lymphocyte trafficking in the pathogenesis of primary sclerosing cholangitis associated with inflammatory bowel disease

Jonathon Graham - American Association for the Study of Liver Diseases (The Liver Meeting) (AASLD) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Primary sclerosing cholangitis

N/A

Filters

45280 Abstracts